Ribavirin Teva Pharma B.V.

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
09-07-2021
Karakteristik produk Karakteristik produk (SPC)
09-07-2021

Bahan aktif:

Ribavirin

Tersedia dari:

Teva B.V.

Kode ATC:

J05AP01

INN (Nama Internasional):

ribavirin

Kelompok Terapi:

Antivirals for systemic use

Area terapi:

Hepatitis C, Chronic

Indikasi Terapi:

Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis C (CHC) in adults (see sections 4.2, 4.4, and 5.1).Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4.2, 4.4 and 5.1).

Ringkasan produk:

Revision: 14

Status otorisasi:

Withdrawn

Tanggal Otorisasi:

2009-07-01

Selebaran informasi

                                70
B. PACKAGE LEAFLET
Medicinal product no longer authorised
71
PACKAGE LEAFLET: INFORMATION FOR THE USER
RIBAVIRIN TEVA PHARMA B.V. 200 MG FILM-COATED TABLETS
ribavirin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Ribavirin Teva Pharma B.V. is and what it is used for
2.
What you need to know before you use Ribavirin Teva Pharma B.V.
3.
How to use Ribavirin Teva Pharma B.V.
4.
Possible side effects
5.
How to store Ribavirin Teva Pharma B.V.
6.
Contents of the pack and other information
1.
WHAT RIBAVIRIN TEVA PHARMA B.V. IS AND WHAT IT IS USED FOR
Ribavirin Teva Pharma B.V. contains the active substance ribavirin.
This medicine stops the
multiplication of hepatitis C virus. Ribavirin Teva Pharma B.V. must
not be used alone.
Depending on the genotype of the hepatitis C virus that you have, your
doctor may choose to treat you
with a combination of this medicine with other medicines. There may be
some further treatment
limitations if you have or have not been previously treated for
chronic hepatitis C infection. Your
doctor will recommend the best course of therapy.
The combination of Ribavirin Teva Pharma B.V. and other medicines is
used to treat patients who
have chronic hepatitis C (HCV).
Ribavirin Teva Pharma B.V. may be used in paediatric patients
(children 3 years of age and older and
adolescents) who are not previously treated and without severe liver
disease.
For paediatric patients (children and adolescents) weighing less than
47 kg a solution formulation is
available.
If 
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
Ribavirin Teva Pharma B.V. 200 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each Ribavirin Teva Pharma B.V. tablet contains 200 mg of ribavirin
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Light pink to pink, (debossed with “93” on one side and “7232”
on the other).
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Ribavirin Teva Pharma B.V. is indicated in combination with other
medicinal products for the treatment of
chronic hepatitis C (CHC) in adults (see sections 4.2, 4.4, and 5.1).
Ribavirin Teva Pharma B.V. is indicated in combination with other
medicinal products for the treatment of
chronic hepatitis C (CHC) for paediatric patients (children 3 years of
age and older and adolescents) not
previously treated and without liver decompensation (see sections 4.2,
4.4 and 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Treatment should be initiated, and monitored, by a physician
experienced in the management of chronic
hepatitis C.
Posology
Ribavirin Teva Pharma B.V. must be used in combination therapy as
described in section 4.1.
Please refer to the corresponding Summary of Product Characteristics
(SmPC) of medicinal products used
in combination with Ribavirin Teva Pharma B.V. for additional
prescribing information particular to that
product and for further dosage recommendations on co-administration
with Ribavirin Teva Pharma B.V.
Ribavirin Teva Pharma B.V. tablets are to be administered orally each
day in two divided doses (morning
and evening) with food.
_Adults: _
The recommended dose and duration of Ribavirin Teva Pharma B.V.
depends on patient’s weight and on
the medicinal product that is used in combination. Please refer to the
corresponding SmPC of medicinal
products used in combination with Ribavirin Teva Pharma B.V.
In the cases in which no specific dose recommendation is made, the
following dose should 
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 09-07-2021
Karakteristik produk Karakteristik produk Bulgar 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Bulgar 09-07-2021
Selebaran informasi Selebaran informasi Spanyol 09-07-2021
Karakteristik produk Karakteristik produk Spanyol 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Spanyol 09-07-2021
Selebaran informasi Selebaran informasi Cheska 09-07-2021
Karakteristik produk Karakteristik produk Cheska 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Cheska 09-07-2021
Selebaran informasi Selebaran informasi Dansk 09-07-2021
Karakteristik produk Karakteristik produk Dansk 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Dansk 09-07-2021
Selebaran informasi Selebaran informasi Jerman 09-07-2021
Karakteristik produk Karakteristik produk Jerman 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Jerman 09-07-2021
Selebaran informasi Selebaran informasi Esti 09-07-2021
Karakteristik produk Karakteristik produk Esti 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Esti 09-07-2021
Selebaran informasi Selebaran informasi Yunani 09-07-2021
Karakteristik produk Karakteristik produk Yunani 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Yunani 09-07-2021
Selebaran informasi Selebaran informasi Prancis 09-07-2021
Karakteristik produk Karakteristik produk Prancis 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Prancis 09-07-2021
Selebaran informasi Selebaran informasi Italia 09-07-2021
Karakteristik produk Karakteristik produk Italia 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Italia 09-07-2021
Selebaran informasi Selebaran informasi Latvi 09-07-2021
Karakteristik produk Karakteristik produk Latvi 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Latvi 09-07-2021
Selebaran informasi Selebaran informasi Lituavi 09-07-2021
Karakteristik produk Karakteristik produk Lituavi 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Lituavi 09-07-2021
Selebaran informasi Selebaran informasi Hungaria 09-07-2021
Karakteristik produk Karakteristik produk Hungaria 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Hungaria 09-07-2021
Selebaran informasi Selebaran informasi Malta 09-07-2021
Karakteristik produk Karakteristik produk Malta 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Malta 09-07-2021
Selebaran informasi Selebaran informasi Belanda 09-07-2021
Karakteristik produk Karakteristik produk Belanda 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Belanda 09-07-2021
Selebaran informasi Selebaran informasi Polski 09-07-2021
Karakteristik produk Karakteristik produk Polski 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Polski 09-07-2021
Selebaran informasi Selebaran informasi Portugis 09-07-2021
Karakteristik produk Karakteristik produk Portugis 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Portugis 09-07-2021
Selebaran informasi Selebaran informasi Rumania 09-07-2021
Karakteristik produk Karakteristik produk Rumania 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Rumania 09-07-2021
Selebaran informasi Selebaran informasi Slovak 09-07-2021
Karakteristik produk Karakteristik produk Slovak 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Slovak 09-07-2021
Selebaran informasi Selebaran informasi Sloven 09-07-2021
Karakteristik produk Karakteristik produk Sloven 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Sloven 09-07-2021
Selebaran informasi Selebaran informasi Suomi 09-07-2021
Karakteristik produk Karakteristik produk Suomi 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Suomi 09-07-2021
Selebaran informasi Selebaran informasi Swedia 09-07-2021
Karakteristik produk Karakteristik produk Swedia 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Swedia 09-07-2021
Selebaran informasi Selebaran informasi Norwegia 09-07-2021
Karakteristik produk Karakteristik produk Norwegia 09-07-2021
Selebaran informasi Selebaran informasi Islandia 09-07-2021
Karakteristik produk Karakteristik produk Islandia 09-07-2021
Selebaran informasi Selebaran informasi Kroasia 09-07-2021
Karakteristik produk Karakteristik produk Kroasia 09-07-2021
Laporan Penilaian publik Laporan Penilaian publik Kroasia 09-07-2021

Peringatan pencarian terkait dengan produk ini